All the Active Ingredient Drugs
Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml. PRE-FILL. PENS: 5. Init. 0.6 mg dly. The dose should be incr. to 3.0 mg dly. in increm. of 0.6 mg with at least one week interv. to improve GI tolerabil. If escal. to the next dose step is not tolerated for two consec. wks., consider discount. tmt. Dly. doses higher than 3.0 mg are not recomm.
As an adjun. a reduced-calorie diet and incr. phys. active. for weight manag. in adult pts. with an init. BMI of ≥ 30 kg/m² (obese), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid. such as dysglycaemia (pre-diab. or type 2 diab. mell.), hypertens. or dyslipidaemia, and who have failed a prev. weight manag. intervent. Tmt. should be discount. after 12 wks. on the 3.0 mg/day dose if pts. have not lost at least 5% of their init. bdy. wt.
GLP-1 Receptor Agonist. Liraglutide 6 mg/ml. PRE-FILLED PEN (sol. for inject): 30 doses
of 0.6 mg, 15 doses of 1.2 mg, or 10
doses of 1.8 mg. Initial: 0.6 mg S.C. 1 x dly for 1 wk, then incr. to 1.2 mg S.C. 1
x dly for at least 1 wk. Max dose 1.8 mg
S.C. 1 x dly.
Tmt. adults with type 2 diabetes mellitus
to achieve glycem. control. In comb.
with: Metformin or sulphonylurea, in pts
with insuff. glycem. control despite max.
tolerat. dose of monother. with
metformin or sulphonylurea; In
combinat. with metformin and a
sulphonylurea/thiazolidinedione in pts
with insuff. glycem. control despite dual
Insulin. Insulin Degludec 100 U/ml, Liraglutide 3.6 mg /ml. PRE-FILL. PEN: 1×3 mL (eq.to Insulin
Degludec 300 UN + Liraglutide 10.8
mg). The drug admin. as dose steps. Add-on to oral glucose-low. med. products Init. dose is 10 dose steps (10 units insulin degludec and 0.36 mg liraglutide). One dose step cont. 1 UN of insulin degludec and 0.036 mg of liraglutide. The max. dly. dose is 50 dose steps (50 UN insulin degludec and 1.8 mg liraglutide). The dose counter on the pen shows the number of dose steps. Dosage must be ajust. individ.
Tmt. of adult. with type 2 diab. mell. to improve glycaem. control in comb. with oral glucose-low. med. products when these alone or comb. with a GLP-1 receptor ag. or basal insulin do not provide adeq. glycaemic control